Aibana Omowunmi, Bachmaha Mariya, Krasiuk Viatcheslav, Rybak Natasha, Flanigan Timothy P, Petrenko Vasyl, Murray Megan B
Division of General Internal Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
Brown University School of Public Health, Providence, RI, USA.
BMC Infect Dis. 2017 Feb 7;17(1):129. doi: 10.1186/s12879-017-2230-2.
Ukraine is among ten countries with the highest burden of multidrug- resistant TB (MDR-TB) worldwide. Treatment success rates for MDR-TB in Ukraine remain below global success rates as reported by the World Health Organization. Few studies have evaluated predictors of poor MDR-TB outcomes in Ukraine.
We conducted a retrospective analysis of patients initiated on MDR-TB treatment in the Kyiv Oblast of Ukraine between January 01, 2012 and March 31st, 2015. We defined good treatment outcomes as cure or completion and categorized poor outcomes among those who died, failed treatment or defaulted. We used logistic regression analyses to identify baseline patient characteristics associated with poor MDR-TB treatment outcomes.
Among 360 patients, 65 (18.1%) achieved treatment cure or completion while 131 (36.4%) died, 115 (31.9%) defaulted, and 37 (10.3%) failed treatment. In the multivariate analysis, the strongest baseline predictors of poor outcomes were HIV infection without anti-retroviral therapy (ART) initiation (aOR 10.07; 95% CI 1.20-84.45; p 0.03) and presence of extensively-drug resistant TB (aOR 9.19; 95% CI 1.17-72.06; p 0.03). HIV-positive patients initiated on ART were not at increased risk of poor outcomes (aOR 1.43; 95% CI 0.58-3.54; p 0.44). There was no statistically significant difference in risk of poor outcomes among patients who received baseline molecular testing with Gene Xpert compared to those who were not tested (aOR 1.31; 95% CI 0.63-2.73).
Rigorous compliance with national guidelines recommending prompt initiation of ART among HIV/TB co-infected patients and use of drug susceptibility testing results to construct treatment regimens can have a major impact on improving MDR-TB treatment outcomes in Ukraine.
乌克兰是全球耐多药结核病(MDR-TB)负担最高的十个国家之一。据世界卫生组织报告,乌克兰耐多药结核病的治疗成功率仍低于全球成功率。很少有研究评估乌克兰耐多药结核病治疗效果不佳的预测因素。
我们对2012年1月1日至2015年3月31日期间在乌克兰基辅州开始接受耐多药结核病治疗的患者进行了回顾性分析。我们将良好的治疗结果定义为治愈或完成治疗,并将死亡、治疗失败或违约患者的结果归类为不佳。我们使用逻辑回归分析来确定与耐多药结核病治疗效果不佳相关的基线患者特征。
在360名患者中,65名(18.1%)实现了治疗治愈或完成,而131名(36.4%)死亡,115名(31.9%)违约,37名(10.3%)治疗失败。在多变量分析中,治疗效果不佳的最强基线预测因素是未开始抗逆转录病毒治疗(ART)的艾滋病毒感染(调整后比值比[aOR]为10.07;95%置信区间[CI]为1.20-84.45;P=0.03)和广泛耐药结核病的存在(aOR为9.19;95%CI为1.17-72.06;P=0.03)。开始接受ART治疗的艾滋病毒阳性患者治疗效果不佳的风险并未增加(aOR为1.43;95%CI为0.58-3.54;P=0.44)。与未接受检测的患者相比,接受基于Gene Xpert的基线分子检测的患者治疗效果不佳的风险没有统计学上的显著差异(aOR为1.31;95%CI为0.63-2.73)。
严格遵守国家指南中关于艾滋病毒/结核病合并感染患者及时开始ART治疗以及使用药敏试验结果制定治疗方案的建议,可能会对改善乌克兰耐多药结核病的治疗效果产生重大影响。